Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4463630 | 0.80 | MAPK8 (0.37) | NQO1ALDH1A1SMN1; SMN2 | |
| SCHEMBL23674802 | 0.80 | NQO1 (0.34) | NQO1KDM4EHPGDSMN1; SMN2S1PR4 | |
| SCHEMBL17529636 | 0.78 | ADORA2A (0.35) | NQO1HPGDSMN1; SMN2GRM5 | |
| SCHEMBL17529638 | 0.78 | NQO1 (0.33) | NQO1L3MBTL1 | |
| SCHEMBL28317673 | 0.78 | HTT (0.32) | SMN1; SMN2 | |
| SCHEMBL2888774 | 0.77 | GRM5 (0.36) | NQO1GRM5 | |
| SCHEMBL1464459 | 0.77 | — | — | |
| SCHEMBL2885102 | 0.76 | NCF1 (0.32) | NQO1KDM4EALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL17529613 | 0.74 | CTSS (0.36) | NQO1KDM4EALDH1A1KMT2AHPGD | |
| SCHEMBL1273848 | 0.74 | GRM5 (0.39) | NQO1KDM4EALDH1A1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486931-B2 | Substituted oxindole compounds | ABBOTT GMBH & CO. KG (DE) | 2013-07-16 | — | — | US | claimed |
| US-20100286165-A1 | SUBSTITUTED OXINDOLE COMPOUNDS | ABBOTT GMBH & CO. KG (DE) | 2010-11-11 | — | — | US | claimed |
| WO-2008107399-A1 | SUBSTITUTED OXINDOLE COMPOUNDS | ABBOTT GMBH & CO. KG (DE) | 2008-09-12 | — | — | WO | claimed |
| EP-2990404-B1 | TETRAZOLINONE COMPOUND AND USE OF SAME | SUMITOMO CHEMICAL CO (JP) | 2020-05-27 | — | — | EP | disclosed |
| US-9867372-B2 | Tetrazolinone compound and use of same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-01-16 | — | — | US | disclosed |
| EP-3046919-A1 | N-ACYLIMINO HETEROCYCLIC COMPOUNDS | BASF SE (DE) | 2016-07-27 | — | — | EP | disclosed |
| US-20160081339-A1 | TETRAZOLINONE COMPOUND AND USE OF SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-03-24 | — | — | US | disclosed |
| EP-2990404-A1 | TETRAZOLINONE COMPOUND AND USE OF SAME | Sumitomo Chemical Company Limited (JP) | 2016-03-02 | — | — | EP | disclosed |
| CN-105339359-A | Tetrazolinone compound and use of same | SUMITOMO CHEMICAL CO | 2016-02-17 | — | — | CN | disclosed |
| WO-2015040116-A1 | N-ACYLIMINO HETEROCYCLIC COMPOUNDS | BASF SE (DE) | 2015-03-26 | — | — | WO | disclosed |
| US-8486931-B2 | Substituted oxindole compounds | ABBOTT GMBH & CO. KG (DE) | 2013-07-16 | — | — | US | disclosed |
| US-20100286165-A1 | SUBSTITUTED OXINDOLE COMPOUNDS | ABBOTT GMBH & CO. KG (DE) | 2010-11-11 | — | — | US | disclosed |
| WO-2008107399-A1 | SUBSTITUTED OXINDOLE COMPOUNDS | ABBOTT GMBH & CO. KG (DE) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286165-A1 | SUBSTITUTED OXINDOLE COMPOUNDS | OXTR, AVPR2, AVPR1A | NQO1 410/4885KDM4E 4463/4885NFKB1 875/4885 |
| US-20160081339-A1 | TETRAZOLINONE COMPOUND AND USE OF SAME | MT-CO1, SOD1, MT-CO2 | NQO1 541/4885KDM4E 2422/4885NFKB1 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.